Study of Crizotinib in Children and Adolescents With Myofibroblastic Tumors

NCT03874273 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Myofibroblastic Tumor

Interventions

DRUG: Crizotinib

Sponsor

Federal Research Institute of Pediatric Hematology, Oncology and Immunology